prior_authorization_form_for_alpha1_antitrypsin_deficiency_medications
A Cigna prior authorization request form to collect clinical and administrative information for coverage review of alpha1-antitrypsin (AAT) augmentation therapies (Aralast NP, Glassia, Prolastin C, Zemaira) and related variants; includes required documentation checkboxes, administration site, dispensing source, diagnoses, and attestations used to process PA requests.
No material clinical/coverage changes
Policy summary and purpose
This is a Cigna prior authorization request form to collect clinical and administrative information for coverage review of alpha1-antitrypsin (AAT) augmentation therapies (Aralast NP, Glassia, Prolastin C, Zemaira) and related variants. The form includes required documentation checkboxes for baseline AAT level and genotype/phenotype, indication selection (eg, emphysema/COPD, panniculitis), disease-specific criteria (lung-function or oxygen requirement for emphysema; biopsy and severity for panniculitis), prior-therapy trial requirements, medication selection (vial sizes and product), administration site and dispensing source, facility/dispensing details, and prescriber attestations and signature used to process PA requests.